Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer

Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer

Treatment options for patients with castration-resistant prostate cancer (CRPC) are limited. The purpose of our study was to investigate the safety and efficacy in terms of prostate-specific antigen (PSA) response of a low-dose oral combination of etoposide and prednisone in patients with CRPC. Thir...

Full description

Bibliographic Details
Main Authors: Yi-Ping Zhu, Xu-Dong Yao, Shi-Lin Zhang, Bo Dai, Hai-Liang Zhang, Yi-Jun Shen, Yao Zhu, Guo-Hai Shi, Guo-Wen Lin, Ding-Wei Ye
Format: Article
Language:English
Published: Wiley 2014-02-01
Series:Kaohsiung Journal of Medical Sciences
Subjects:
Castration-resistant prostate cancer
Chemotherapy
Etoposide
Oral
Online Access:http://www.sciencedirect.com/science/article/pii/S1607551X13001666

Internet

http://www.sciencedirect.com/science/article/pii/S1607551X13001666

Similar Items